https://endpts.com/merck-looks-to-ditch-the-needles-with-its-next-gen-oral-pcsk9-inhibitor-for-high-cholesterol/?utm_medium=email&utm_campaign=1351%20%20BioNTech%20founder%20on%20building%20new%20class%20of%20mRNA%20drugs%20AHA%20Moderna%20AstraZeneca%20raise%20the%20curtain%20on%20an%20mRNA%20cardio%20player%20Basic&utm_content=1351%20%20BioNTech%20founder%20on%20building%20new%20class%20of%20mRNA%20drugs%20AHA%20Moderna%20AstraZeneca%20raise%20the%20curtain%20on%20an%20mRNA%20cardio%20player%20Basic+CID_b437523d80f4ae543d0f0c02291ef653&utm_source=ENDPOINTS%20emails&utm_term=Merck%20looks%20to%20ditch%20the%20needles%20with%20its%20next-gen%20oral%20PCSK9%20inhibitor%20for%20high%20cholesterol
Seems like Merck have a decent competitor compound in this space.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.025(10.0%) |
Mkt cap ! $47.45M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 22.5¢ | $209.3K | 892.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7150 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 416666 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |